Safety & Efffficacy of Genakumab in Patients With Frequent Flares

PHASE3CompletedINTERVENTIONAL

Enrollment

313

Participants

Timeline

Start Date

January 11, 2023

Primary Completion Date

April 3, 2024

Study Completion Date

April 3, 2024

Conditions

Acute Gout Arthritis

Interventions

DRUG

genakumab

200mg s.c.

DRUG

placebo for Diprospan

i.m.

DRUG

placebo for genakumab

s.c.

DRUG

Diprospan

7mg i.m.

Trial Locations (1)

Fudan University Affiliated Huashan Hospital, Shanghai

All Listed Sponsors

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY